Bruker (BRKR) Gets a Buy from Bank of America Securities
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Bruker (BRKR – Research Report). The ...
Le Lézard2d
Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the ...
Canada4d
Scientific Research and Experimental Development (SR&ED) tax incentives
The Scientific Research and Experimental Development (SR&ED) tax incentives are intended to encourage businesses to conduct research and development in Canada. Corporations, individuals, trusts, and ...
Bruker price target lowered to $65 from $69 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...